1700020O03Rik Inhibitors
Chemical inhibitors of 1700020O03Rik can serve as tools to understand the functional role of this protein in cellular processes by selectively blocking its activity. Palbociclib, for instance, can arrest the cell cycle at the G1 phase by inhibiting CDK4/6, which may be crucial for the activity of 1700020O03Rik if it is associated with cell cycle progression. Rapamycin, by suppressing the mTOR signaling pathway, can disrupt processes that are essential for protein synthesis and cell growth, leading to the functional inhibition of 1700020O03Rik if it relies on mTOR-mediated signals. Similarly, Trametinib and U0126, both inhibitors of MEK1/2, prevent the activation of the MAPK/ERK pathway. This inhibition can have a downstream effect on the activity of 1700020O03Rik if it operates within this signaling cascade. LY294002, targeting the PI3K/Akt pathway, can also impede the function of 1700020O03Rik by obstructing critical survival and proliferation signals.
Additionally, Dasatinib's inhibition of Src family kinases can lead to a functional block of 1700020O03Rik if its activity is coupled with Src kinase-mediated signaling. Erlotinib, which targets EGFR, can have a similar effect by disrupting proliferation and differentiation signals that 1700020O03Rik may depend on. Sorafenib's broad kinase inhibition, including RAF kinases, and Sunitinib's targeting of receptor tyrosine kinases such as PDGF and VEGF receptors, can interfere with 1700020O03Rik's functionality if it is associated with pathways involving these kinases. PD98059, another MEK inhibitor, along with SB203580, which inhibits p38 MAP kinase, and SP600125, which acts on the JNK pathway, can all modulate the functional activity of 1700020O03Rik. These chemicals can alter the protein's activity by impeding the signaling pathways that contribute to cellular stress responses, proliferation, and apoptosis, which 1700020O03Rik may be a part of or influenced by.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By inhibiting these kinases, the cell cycle is arrested at the G1 phase, which can lead to the inhibition of 1700020O03Rik if its activity is linked to cell cycle progression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress the mTOR signaling pathway. Since mTOR regulates many cellular processes including protein synthesis and cell growth, inhibition of mTOR can lead to functional inhibition of 1700020O03Rik if it relies on mTOR-mediated signaling for its activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib acts as an inhibitor of MEK1/2, which are part of the MAPK/ERK pathway. Inhibition of this pathway can result in the inhibition of downstream proteins involved in cell proliferation and differentiation, potentially including 1700020O03Rik if it is functionally dependent on this signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can block the PI3K/Akt signaling pathway. This pathway is critical for various cellular functions, including survival, proliferation, and growth. Inhibition of PI3K can functionally inhibit 1700020O03Rik if the protein's activity is contingent upon signals from the PI3K/Akt pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases are involved in numerous signaling pathways that regulate various cellular processes, including proliferation, differentiation, and survival. By inhibiting Src kinases, Dasatinib can functionally inhibit 1700020O03Rik if the protein's activity is coupled to Src kinase-mediated signaling. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR inhibitor. The EGFR signaling pathway plays a key role in cellular processes like proliferation and differentiation. Inhibition of EGFR can lead to the functional inhibition of 1700020O03Rik if it is dependent on EGFR-mediated signaling for its activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple kinases, including RAF kinases, VEGFR, and PDGFR. By inhibiting these kinases, it can interfere with the RAF/MEK/ERK signaling pathway, among others, leading to inhibition of cell proliferation and angiogenesis. This could functionally inhibit 1700020O03Rik if its activity is dependent on these pathways. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that targets PDGF receptors, VEGF receptors, and others. By inhibiting these kinases, Sunitinib can disrupt signaling pathways that are essential for cell proliferation and angiogenesis, which could lead to the functional inhibition of 1700020O03Rik if the protein's activity is mediated through these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of MAPK/ERK signaling. The inhibition of this pathway can lead to the functional inhibition of 1700020O03Rik if the protein operates downstream of or in conjunction with the MAPK/ERK signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is implicated in the response to stress stimuli and cytokines. If 1700020O03Rik is involved in cellular responses mediated by p38 MAP kinase signaling, inhibition by SB203580 can lead to its functional inhibition. | ||||||